MYOV Myovant Sciences Ltd.

5.530.26 (+4.84%)
IEX real time price: 1:31:46 PM

Quote

Previous Close
$5.27
Day Range
$5.19-$5.69
52 Week Range
$4.57-$26.02
Volume
449,628
Avg Volume
445,797
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$398.89M
Enterprise Value (EV)
$323.79M
PE Ratio
-
EV/EBITDA
-1.22
Price/Sales
-
Price/Book
87.79
PEG Ratio
0.14

Financials

Revenue
-
Gross Profit
-$438.00K
EBITDA
-$264.39M
EPS, ttm
-$3.99
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/7/2019 (23 days)
Debt to Equity
2,293%
Debt
$80.97M
Cash
$156.07M
Net Debt
-

Performance

Beta
0.70
200 Day Moving Avg
$13.72
50 Day Moving Avg
$6.55
52 Week Change
-75.51%
YTD Change
-64.03%
1 Month Change
-11.73%
3 Month Change
-40.25%
6 Month Change
-74.82%
1 Year Change
-75.51%
2 Year Change
-63.38%
5 Year Change
-60.26%

Share Count

Shares Outstanding
72.2M
Float
29.0M
Restricted Shares
43.2M
Restricted Shares, %
59.81%

Myovant Sciences Ltd. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Lynn Seely

Website: http://www.myovant.com

Description: Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Employees: 167

Latest News